Table 3.
Therapy Utilization Patterns at Baseline and in Follow-up Among Patients With Chronic Pouchitis and CD of the Pouch in a Multicenter Cohort
| Therapy Use at Enrollment, Chronic Pouchitis (n = 96) | Therapy Use at Enrollment, CD of the Pouch (n = 192) | New Therapy Initiated in Follow-up, Chronic Pouchitis (n = 96) | New Therapy Initiated in Follow-up, CD of the Pouch (n = 192) | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| Antibioticsa | ||||||||
| Ciprofloxacin | 36 | 38 | 44 | 23 | 7 | 7 | 11 | 6 |
| Metronidazole | 22 | 23 | 18 | 9 | 4 | 4 | 7 | 4 |
| Other antibiotic | 18 | 19 | 15 | 8 | 9 | 9 | 14 | 7 |
| Probiotics | 21 | 22 | 29 | 15 | 6 | 6 | 9 | 5 |
| Methotrexate | 6 | 6 | 24 | 12 | 2 | 2 | 7 | 4 |
| Thiopurine | 5 | 5 | 47 | 25 | 2 | 2 | 14 | 7 |
| Anti-TNF | 11 | 11 | 97 | 51 | 11 | 11 | 32 | 17 |
| Ustekinumab | 0 | 0 | 1 | 1 | 0 | 0 | 14 | 7 |
| Vedolizumab | 0 | 0 | 5 | 3 | 3 | 3 | 18 | 9 |
aAmong patients taking antibiotics, 40 patients were taking a combination of at least 2 antibiotics at enrollment.